Journal article icon

Journal article

Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes

Abstract:

Background

The Scottish Medicines Consortium evaluates new drugs for use in the National Health Service in Scotland. Reforms in 2014 to their evaluation process aimed to increase patient access to new drugs for end-of-life or rare conditions; the changes include additional steps in the process to gain further information from patients and clinicians, and for revised commercial agreements. This study examines the extent of any impact of the reforms on funding decisions.

Me...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Publisher's version

Actions


Access Document


Files:
Publisher copy:
10.1186/s12913-017-2561-0

Authors


More by this author
Department:
Oxford, MSD, RDM, RDM - Investigative Medicine Division
Role:
Author
More by this author
Department:
Oxford, MSD, Nuffield Department of Population Health
Role:
Author
More by this author
Department:
Oxford, MSD, Divisional Administration, Medical Sciences Div Office
Role:
Author
More by this author
Department:
Oxford, MSD, Primary Care, Primary Care Health Sciences
Role:
Author
More by this author
Department:
Oxford, MSD, RDM, RDM - Investigative Medicine Division
Role:
Author
Cancer Research UK More from this funder
Publisher:
BioMed Central Publisher's website
Journal:
BMC Health Services Research Journal website
Volume:
17
Pages:
613
Publication date:
2017-08-05
Acceptance date:
2017-08-21
DOI:
ISSN:
1472-6963
Pubs id:
pubs:725631
URN:
uri:06afb578-5f24-4197-9ed0-de0b46bc0ed1
UUID:
uuid:06afb578-5f24-4197-9ed0-de0b46bc0ed1
Local pid:
pubs:725631

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP